Asset Details
Do you wish to reserve the book?
Lev Pharmaceuticals Licenses IVIG Technology
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Lev Pharmaceuticals Licenses IVIG Technology
Do you wish to request the book?
Lev Pharmaceuticals Licenses IVIG Technology
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Newsletter
Lev Pharmaceuticals Licenses IVIG Technology
2006
Overview
Lev is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. Lev's product candidates are based on C1-esterase inhibitor (\"C1-INH\"), a human plasma protein that mediates inflammation and is potentially applicable as a treatment for a range of medical indications. The Company is currently conducting a registrational Phase III clinical trial of its lead product candidate, C1-INH for the acute and prophylactic treatment of hereditary angioedema, a genetic disease affecting 6,000 or more people in the U.S. Lev is also evaluating the development of C1-INH for the treatment of acute myocardial infarction, or heart attack, and selective other diseases and disorders in which inflammation is known or believed to play an underlying role.
Publisher
Business Wire
